SAN DIEGO, Feb. 14, 2019 /PRNewswire/ — Decipher Biosciences (formerly GenomeDx Inc.), a leader in the field of urologic cancer genomics, today announced that it will present results from seven studies featuring its Decipher® Prostate and Bladder C… […]
Webcast scheduled for Wednesday, February 27 at 11:30 a.m. Eastern Time
CARLSBAD, Calif., Feb. 13, 2019 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 27th at 11:30 a… […]
SAN DIEGO, Feb. 12, 2019 /PRNewswire/ — Epic Sciences, Inc. (Epic) announced today the presentation of four posters at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), held in San Francisco on February 14-1… […]
Funds will go toward recruiting top researchers and improving facilities in the South Bay region of LA County – one of the nation’s top ten biotech clusters
LOS ANGELES, Feb. 11, 2019 /PRNewswire/ — Southern California philanthropists Melanie and Ri… […]
SAN DIEGO, Feb. 8, 2019 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 6,250,000 shares of its co… […]
SAN DIEGO, Feb. 7, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology Day in New York on Thursday, February 14th at… […]
-Barry Quart, Pharm.D., Chief Executive Officer of Heron, to take on additional role of President-
SAN DIEGO, Feb. 5, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the live… […]
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $130.3 Million with Approximately 22,900 TRxINGREZZA® (valbenazine) Full-Year 2018 Net Product Sales of $409.6 Million with Approximately 71,500 TRxCongenital Adrenal Hyperplasia Phase II Stud… […]
Peer-reviewed article in journal, Clinics in Oncology, further supports the clinical utility of Biocept’s Target Selector(TM) platform to aid physicians in the selection of targeted therapy for patients with lung cancer
SAN DIEGO, Feb. 5, 2019 /PRNew… […]
— argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn —
BREDA, the Netherlands and GHENT, Belgium and S… […]
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
